StreetInsider.com News Articles http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 26 Aug 2026 16:06:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif StreetInsider.com News Articles http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday Form 8-K Inhibikase Therapeutics, For: Aug 21 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibikase+Therapeutics%2C++For%3A+Aug+21/26981622.html si-local-file:///var/storage/secattach/20260826/26981622.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibikase+Therapeutics%2C++For%3A+Aug+21/26981622.html Wed, 26 Aug 2026 16:06:00 -0400 IKT O.48149183 Form 8-K Inhibikase Therapeutics, For: Aug 21 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibikase+Therapeutics%2C++For%3A+Aug+21/26981622.html si-local-file:///var/storage/secattach/20260826/26981622.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibikase+Therapeutics%2C++For%3A+Aug+21/26981622.html Wed, 26 Aug 2026 16:06:00 -0400 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26932841.html si-local-file:///var/storage/secattach/20260814/26932841.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26932841.html Fri, 14 Aug 2026 17:23:00 -0400 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: PERCEPTIVE ADVISORS LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26932841.html si-local-file:///var/storage/secattach/20260814/26932841.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+PERCEPTIVE+ADVISORS+LLC/26932841.html Fri, 14 Aug 2026 17:23:00 -0400 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Nantahala Capital Management, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932114.html si-local-file:///var/storage/secattach/20260814/26932114.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932114.html Fri, 14 Aug 2026 16:48:00 -0400 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Nantahala Capital Management, LLC http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932114.html si-local-file:///var/storage/secattach/20260814/26932114.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Nantahala+Capital+Management%2C+LLC/26932114.html Fri, 14 Aug 2026 16:48:00 -0400 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Sands+Capital+Life+Sciences+Pulse+Fund+II%2C+L.P./26918797.html si-local-file:///var/storage/secattach/20260813/26918797.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Sands+Capital+Life+Sciences+Pulse+Fund+II%2C+L.P./26918797.html Thu, 13 Aug 2026 11:49:00 -0400 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: Sands Capital Life Sciences Pulse Fund II, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Sands+Capital+Life+Sciences+Pulse+Fund+II%2C+L.P./26918797.html si-local-file:///var/storage/secattach/20260813/26918797.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+Sands+Capital+Life+Sciences+Pulse+Fund+II%2C+L.P./26918797.html Thu, 13 Aug 2026 11:49:00 -0400 IKT O.48149183 Inhibikase Therapeutics (IKT) Reports In-Line Q2 EPS http://www.streetinsider.com/Earnings/Inhibikase+Therapeutics+%28IKT%29+Reports+In-Line+Q2+EPS/26906928.html <p>Inhibikase Therapeutics (NASDAQ: IKT) reported Q2 EPS of ($0.11), in-line with the analyst estimate of ($0.11).</p><p>For earnings history and earnings-related data on Inhibikase Therapeutics (IKT) <a href="http://www.streetinsider.com/ec_earnings.php?q=IKT">click here</a>.</p> http://www.streetinsider.com/Earnings/Inhibikase+Therapeutics+%28IKT%29+Reports+In-Line+Q2+EPS/26906928.html Tue, 11 Aug 2026 17:05:45 -0400 IKT Form S-8 Inhibikase Therapeutics, http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Inhibikase+Therapeutics%2C+++++++++++++/26906252.html si-local-file:///var/storage/secattach/20260811/26906252.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Inhibikase+Therapeutics%2C+++++++++++++/26906252.html Tue, 11 Aug 2026 16:28:00 -0400 IKT O.48149183 Form S-8 Inhibikase Therapeutics, http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Inhibikase+Therapeutics%2C+++++++++++++/26906252.html si-local-file:///var/storage/secattach/20260811/26906252.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Inhibikase+Therapeutics%2C+++++++++++++/26906252.html Tue, 11 Aug 2026 16:28:00 -0400 IKT O.48149183 Form 10-Q Inhibikase Therapeutics, For: Jun 30 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Inhibikase+Therapeutics%2C++For%3A+Jun+30/26906041.html si-local-file:///var/storage/secattach/20260811/26906041.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Inhibikase+Therapeutics%2C++For%3A+Jun+30/26906041.html Tue, 11 Aug 2026 16:18:00 -0400 IKT O.48149183 Form 10-Q Inhibikase Therapeutics, For: Jun 30 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Inhibikase+Therapeutics%2C++For%3A+Jun+30/26906041.html si-local-file:///var/storage/secattach/20260811/26906041.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Inhibikase+Therapeutics%2C++For%3A+Jun+30/26906041.html Tue, 11 Aug 2026 16:18:00 -0400 IKT O.48149183 Form 8-K Inhibikase Therapeutics, For: Aug 11 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibikase+Therapeutics%2C++For%3A+Aug+11/26905736.html si-local-file:///var/storage/secattach/20260811/26905736.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibikase+Therapeutics%2C++For%3A+Aug+11/26905736.html Tue, 11 Aug 2026 16:09:00 -0400 IKT O.48149183 Form 8-K Inhibikase Therapeutics, For: Aug 11 http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibikase+Therapeutics%2C++For%3A+Aug+11/26905736.html si-local-file:///var/storage/secattach/20260811/26905736.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Inhibikase+Therapeutics%2C++For%3A+Aug+11/26905736.html Tue, 11 Aug 2026 16:09:00 -0400 IKT O.48149183 Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity http://www.streetinsider.com/Press+Releases/Inhibikase+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Highlights+Recent+Activity/26905397.html <p align="justify">WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.</p> <p align="justify">“During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “Also, during the quarter, http://www.streetinsider.com/Press+Releases/Inhibikase+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Highlights+Recent+Activity/26905397.html Tue, 11 Aug 2026 16:01:00 -0400 IKT IKT Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity http://www.streetinsider.com/Press+Releases/Inhibikase+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Highlights+Recent+Activity/26905397.html <p align="justify">WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.</p> <p align="justify">“During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “Also, during the quarter, http://www.streetinsider.com/Press+Releases/Inhibikase+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Highlights+Recent+Activity/26905397.html Tue, 11 Aug 2026 16:01:00 -0400 IKT IKT Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity http://www.streetinsider.com/Globe+Newswire/Inhibikase+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Highlights+Recent+Activity/26905397.html <p align="justify">WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.</p> <p align="justify">“During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “Also, during the quarter, http://www.streetinsider.com/Globe+Newswire/Inhibikase+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Highlights+Recent+Activity/26905397.html Tue, 11 Aug 2026 16:01:00 -0400 IKT IKT Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity http://www.streetinsider.com/Globe+Newswire/Inhibikase+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Highlights+Recent+Activity/26905397.html <p align="justify">WILMINGTON, Del., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001, a novel once-daily oral anti-proliferative for Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2026, and highlighted recent developments.</p> <p align="justify">“During our second quarter and in recent weeks we continued to advance our Phase 3 IMPROVE-PAH study with 26 country regulatory approvals together with the recent initiation of 43 clinical sites across a range of countries,” said Mark Iwicki, Chief Executive Officer of Inhibikase. “Also, during the quarter, http://www.streetinsider.com/Globe+Newswire/Inhibikase+Therapeutics+Announces+Second+Quarter+2026+Financial+Results+and+Highlights+Recent+Activity/26905397.html Tue, 11 Aug 2026 16:01:00 -0400 IKT IKT Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26851255.html si-local-file:///var/storage/secattach/20260731/26851255.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26851255.html Fri, 31 Jul 2026 16:34:00 -0400 IKT O.48149183 Form SCHEDULE 13G/A Inhibikase Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P. http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26851255.html si-local-file:///var/storage/secattach/20260731/26851255.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++Inhibikase+Therapeutics%2C+++++++++++++++Filed+by%3A+RA+CAPITAL+MANAGEMENT%2C+L.P./26851255.html Fri, 31 Jul 2026 16:34:00 -0400 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Jul 29 Filed by: Kolchinsky Peter http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jul+29++Filed+by%3A+Kolchinsky+Peter/26851233.html si-local-file:///var/storage/secattach/20260731/26851233.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jul+29++Filed+by%3A+Kolchinsky+Peter/26851233.html Fri, 31 Jul 2026 16:32:00 -0400 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Jul 29 Filed by: Kolchinsky Peter http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jul+29++Filed+by%3A+Kolchinsky+Peter/26851233.html si-local-file:///var/storage/secattach/20260731/26851233.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jul+29++Filed+by%3A+Kolchinsky+Peter/26851233.html Fri, 31 Jul 2026 16:32:00 -0400 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Jul 30 Filed by: BERMAN DENNIS N http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jul+30++Filed+by%3A+BERMAN+DENNIS+N/26850612.html si-local-file:///var/storage/secattach/20260731/26850612.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jul+30++Filed+by%3A+BERMAN+DENNIS+N/26850612.html Fri, 31 Jul 2026 16:05:00 -0400 IKT O.48149183 Form 4 Inhibikase Therapeutics, For: Jul 30 Filed by: BERMAN DENNIS N http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jul+30++Filed+by%3A+BERMAN+DENNIS+N/26850612.html si-local-file:///var/storage/secattach/20260731/26850612.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Inhibikase+Therapeutics%2C++For%3A+Jul+30++Filed+by%3A+BERMAN+DENNIS+N/26850612.html Fri, 31 Jul 2026 16:05:00 -0400 IKT O.48149183